Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant
Authors
Keywords
-
Journal
Nature Communications
Volume 13, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-05-13
DOI
10.1038/s41467-022-30340-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
- (2022) Wilfredo F. Garcia-Beltran et al. CELL
- SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron
- (2022) Alison Tarke et al. CELL
- Omicron’s message on vaccines: Boosting begets breadth
- (2022) Duane R. Wesemann CELL
- Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study
- (2022) Sue Ann Costa Clemens et al. LANCET
- Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
- (2022) Delphine Planas et al. NATURE
- Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
- (2022) Juan Manuel Carreño et al. NATURE
- Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
- (2022) Sandile Cele et al. NATURE
- Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
- (2022) Raquel Viana et al. NATURE
- Why does the Omicron sub-variant spread faster than the original?
- (2022) Ewen Callaway NATURE
- mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
- (2022) Henning Gruell et al. NATURE MEDICINE
- Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant
- (2022) Yu Gao et al. NATURE MEDICINE
- Neutralizing antibodies against the SARS-CoV-2 Omicron variant following homologous and heterologous CoronaVac or BNT162b2 vaccination
- (2022) Samuel M. S. Cheng et al. NATURE MEDICINE
- Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
- (2022) Eddy Pérez-Then et al. NATURE MEDICINE
- SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons
- (2022) Annika Rössler et al. NEW ENGLAND JOURNAL OF MEDICINE
- Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients
- (2022) Corine H. GeurtsvanKessel et al. Science Immunology
- Immunity to SARS-CoV-2 up to 15 months after infection
- (2022) Harold Marcotte et al. iScience
- mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron
- (2022) Matthew Gagne et al. CELL
- Neutralizing antibodies to SARS‐CoV‐2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects
- (2022) Anu Haveri et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Omicron BA.2 (B.1.1.529.2): High Potential for Becoming the Next Dominant Variant
- (2022) Jiahui Chen et al. Journal of Physical Chemistry Letters
- T cell responses to SARS-CoV-2 spike cross-recognize Omicron
- (2022) Roanne Keeton et al. NATURE
- Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
- (2022) Jingyou Yu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines
- (2022) Yannic C. Bartsch et al. Science Translational Medicine
- Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
- (2021) Zhuoming Liu et al. Cell Host & Microbe
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
- (2021) Joana Barros-Martins et al. NATURE MEDICINE
- Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
- (2021) Angela Choi et al. NATURE MEDICINE
- Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
- (2021) Jamie Lopez Bernal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study
- (2021) Kathryn M. Hastie et al. SCIENCE
- A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations
- (2021) Federico Bertoglio et al. Cell Reports
- Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK
- (2021) Angalee Nadesalingam et al. Lancet Microbe
- Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications
- (2021) Aakriti Dubey et al. CURRENT MICROBIOLOGY
- Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves
- (2021) Caroline Maslo et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- CoronaVac efficacy data from Turkey
- (2021) Martina E McMenamin et al. LANCET
- Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
- (2021) Arabella S V Stuart et al. LANCET
- Waning COVID super-immunity raises questions about Omicron
- (2021) Max Kozlov NATURE
- China’s COVID vaccines have been crucial — now immunity is waning
- (2021) Smriti Mallapaty NATURE
- How severe are Omicron infections?
- (2021) Heidi Ledford NATURE
- Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID ‐19 vaccines in Hong Kong
- (2021) Chris Ka Pun Mok et al. RESPIROLOGY
- Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination
- (2021) Chris Davis et al. PLoS Pathogens
- Reinfections in COVID-19 Patients: Impact of Virus Genetic Variability and Host Immunity
- (2021) Aisha Fakhroo et al. Vaccines
- WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community
- (2021) Ivana Knezevic et al. Lancet Microbe
- Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020
- (2020) Elena Percivalle et al. Eurosurveillance
- Clinical And Analytical Performance Of An Automated Serological Test That Identifies S1/S2 Neutralizing IgG In COVID-19 Patients Semiquantitatively.
- (2020) Fabrizio Bonelli et al. JOURNAL OF CLINICAL MICROBIOLOGY
- COVID-19: Mechanisms of Vaccination and Immunity
- (2020) Daniel E. Speiser et al. Vaccines
- Baculovirus-free insect cell expression system for high yield antibody and antigen production
- (2020) Janin Korn et al. Scientific Reports
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started